To the Editor—We read with interest the article by Lewnard et al on reduced risk of coronavirus disease 2019 (COVID-19) among 13-valent pneumococcal conjugate vaccine (PCV13) recipients [1]. This topic is pertinent to the COVID-19 pandemic and could serve as reference for those who may seek more protection from the consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We would like to raise a few points from the article for further discussion.

中文翻译：

---

解释 COVID-19 和疫苗的预防

致编辑——我们感兴趣地阅读了 Lewnard 等人关于降低 13 价肺炎球菌结合疫苗 (PCV13) 接受者患 2019 年冠状病毒病 (COVID-19) 风险的文章 [1]。本主题与 COVID-19 大流行相关，可为那些寻求更多保护以免受严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染后果的人提供参考。我们想从文章中提出几点以供进一步讨论。